Results 201 to 210 of about 74,509 (297)

Recipient Versus Donor CYP3A4/5 Genotypes in Adult Liver Transplant Recipients to Achieve Therapeutic Tacrolimus Concentrations Early Post‐Transplant

Clinical and Translational Science, Volume 18, Issue 9, September 2025.
ABSTRACT Tacrolimus is an immunosuppressive agent with difficult dosing due to a narrow therapeutic index and large interpatient pharmacokinetic variability, for which CYP3A5 variation plays a role. Tacrolimus/CYP3A5 pharmacogenetic guidelines exclude liver transplant patients with a donor/recipient CYP3A5 mismatch. We sought to determine the influence
Eda Eken, Sergio Duarte, Isabella Angeli‐Pahim, Alexandra D. Ladd, Curtis Warren, Taimour Y. Langaee, Ali Zarrinpar, Julie A. Johnson   +7 more
wiley   +1 more source

Editorial: Editor's feature: negative findings in pharmacogenetics and pharmacogenomics volume II. [PDF]

Front Pharmacol
Agúndez JAG, García-Martín E, Quiñones LA.   +2 more
europepmc   +1 more source

Cardiovascular Pharmacogenomics [PDF]

, 2003
Dan M. Roden
openalex   +1 more source

Genomics & Ethnicity: Using a Tool in the U.S. Environmental Protection Agency\u27s Environmental Justice Toolkit [PDF]

, 2007
McMurray, David L., Jr.
core   +1 more source

How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion

Clinical and Translational Science, Volume 18, Issue 9, September 2025.
ABSTRACT Enrolling diverse populations during early clinical trial development and planning for diversity plans could be challenging. In 2024, the Diversity and Inclusion Clinical Pharmacology Leadership Group Working Group (D&I CPLG WG) from The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) collaborated with ...
Michael Z. Liao, Aarti Sawant, Brian Corrigan, Sebastian Haertter, Yasuto Otsubo, Islam R. Younis, Sreeneeranj Kasichayanula, Rashmi Mehta   +7 more
wiley   +1 more source

Editorial: Pharmacogenomics for improving drug safety and efficacy in cancer. [PDF]

Front Pharmacol
He Z, Fu X, Xu Z, Alshargi O, Rodríguez-Labrada R, Zhong XB.   +5 more
europepmc   +1 more source

US FDA contemplates collection of pharmacogenomic data [PDF]

, 2003
Jim Kling
openalex   +1 more source

Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority

Clinical and Translational Science, Volume 18, Issue 9, September 2025.
ABSTRACT Optimal prescribing of drug products requires accurate informative drug labels. One critical aspect of a label is the recommended dosage. We suggest that the final authority for this portion of the label should reside in FDA's Office of Clinical Pharmacology (OCP), rather than in the Office of New Drugs, given that most FDA clinicians do not ...
Mark J. Ratain, Garth W. Strohbehn
wiley   +1 more source

Using pharmacogenomics to personalise drug therapy: which drugs, when and how. [PDF]

Aust Prescr
Stocker SL, Polasek TM.
europepmc   +1 more source

Pharmacogenomics of the immunosuppressive agents

, 2002
Atsuo Taniguchi, Wako Urano, Eiichi Tanaka, Yutaka Kitamura, Masayuki Saito, Hideto Akama, Hishashi Yamanak, Terunobu Saito, Naoyuki Kamatani   +8 more
openalex   +2 more sources